Table 4 Estimated public health and economic impacts of seasonal trivalent influenza vaccination extrapolated to EU-27 countries
From: Annual public health and economic benefits of seasonal influenza vaccination: a European estimate
Influenza-related event | Numbers and costs currently averted at existing VCR (lower, upper limit) | |||
|---|---|---|---|---|
Estimates using effectiveness values | Estimates using efficacy values | |||
Numbers of events averted | Costs averted | Number of events averted | Costs averted | |
Cases of influenza | 1.6 million (0.82; 2.2) | - | 2.1 million (1.3; 2.6) | - |
Influenza-related mortality | 25,161 (10,092; 38,390) | - | 37,165 (21,986; 44,667) | - |
Influenza- related GP visits | 701,234 (417,680; 958,010) | €22 million (13; 30) | 915,997 (620,643; 1,110,498) | €29 million (20; 35) |
Influenza-related hospitalization | 45,325 (19,440; 67,970) | €131 million (56;197) | 65,593 (39,536; 82,036) | €190 million (141; 238) |
Lost days of work | 715,428 (568,878; 881,851) | €96 million (76; 118) | 844,748 (661,843; 973,075) | €113 million (88; 130) |
All Influenza-related costs | - | €248 million (145; 345) | - | €332 million (222; 403) |